Pain and U-Shaped Dose Responses: Occurrence, Mechanisms, and Clinical Implications

REFERENCES

• Angst M. S., Koppert W., Pahl I., Clark D. J., Schmelz M. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 2003; 10: 49–57
   Google Scholar
• Blane G. F., Dugdall D. Interaction of narcotic antagonists and analgesics. J. Pharmacol. Pharm. 1968; 20: 547–552
   PubMed Web of Science ®Google Scholar
• Calabrese E. J. Dopamine: Biphasic dose responses. Crit. Rev. Toxicol. 2001; 31: 563–584
   PubMed Web of Science ®Google Scholar
• Calabrese E. J. Converging concepts: Adaptive response, preconditioning, and the Yerkes-Dodson Law are manifestations of hormesis. Ageing Res. Rev. 2008; 7: 8–20
   PubMed Web of Science ®Google Scholar
• Calabrese E. J., Bachmann K. A., Bailer A. J., Bolger P. M., Borak J., Cai L., Cedergreen N., Cherian M. G., Chiueh C. C., Clarkson T. W., et al. Biological stress terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework. Tox. Appl. Pharmacol 2007; 222: 122–128
   PubMed Web of Science ®Google Scholar
• Calabrese E. J., Baldwin L. A. The frequency of U-shaped dose-responses in the toxicological literature. Tox. Sci. 2001; 62: 330–338
   PubMed Web of Science ®Google Scholar
• Calabrese E. J., Baldwin L. A. The hermetic dose response model is more common than the threshold model in toxicology. Tax. Sci. 2003; 71: 246–250
   PubMed Web of Science ®Google Scholar
• Calabrese E. J., Blain R. The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: An overview. Toxicol. Appl. Pharmacol 2005; 202: 289–301
   PubMed Web of Science ®Google Scholar
• Calabrese E. J., Staudenmayer J. W., Stanek E. J., Hoffmann G. R. Hormesis outperforms threshold model in NCI anti-tumor drug screening data. Tox. Sci. 2006; 94: 368–378
   PubMed Web of Science ®Google Scholar
• Celerier E., Laulin J., Larcher A., Le Moal M., Simonnet G. Evidence for opiate-activated NMDA processes masking opiate analgesia in rats. Brain Res. 1999; 847: 18–25
   PubMed Web of Science ®Google Scholar
• Celerier E., Rivat C., Jun Y., Laulin J. P., Larcher A., Reynier P., Simonnet G. Long-lasting hyperalgesia induced by fentanyl in rats: Preventive effect of ketamine. Anesthesiology 2000; 92: 465–472
   PubMed Web of Science ®Google Scholar
• Celerier E., Laulin J. P., Corcuff J. B., Le Moal M., Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: A sensitization process. J. Neurosci. 2001; 21: 4074–4080
   PubMed Web of Science ®Google Scholar
• Compton P., Athanasos P., Elashoff D. Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: A preliminary study. J. Pain 2003; 4: 511–519
   PubMed Web of Science ®Google Scholar
• Conceicao I. M., Maiolini M., Jr., Mattia N., Vital M. A., Santos B. R., Smaili S., Frussa-Filho R. Anxiety-induced antinociception in the mouse. Braz. J. Med. Biol. Res. 1992; 25: 831–834
   PubMed Web of Science ®Google Scholar
• Cowan A. Buprenorphine: New pharmacological aspects. Int. J. Clin. Proctol. 2003; 133(Suppl)3–8
   Google Scholar
• Cowan A., Lewis J. W., MacFarlane I.R. Agonist and antagonist properties of buprenonphine, a new antinociceptive agent. Br. J. Pharmacol. 1977; 60: 537–545
   PubMed Web of Science ®Google Scholar
• Dennis S. G., Melzack R., Gutman S., Boucher F. Pain modulation by adrenergic agents and morphine as measured by three pain tests. Life Sci. 1980; 26: 1247–1259
   PubMed Web of Science ®Google Scholar
• Dewey W. L. Cannabinoid pharmacology. Pharmacol. Rev. 1986; 38: 151–178
   PubMed Web of Science ®Google Scholar
• Dickenson A. H., Sullivan A. F. Electrophysiological studies on the effects of intrathecal morphine on nociceptive neurons in the rat dorsal horn. Pain 1986; 24: 211–222
   PubMed Web of Science ®Google Scholar
• Dum J. E., Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br. J. Pharmacol. 1981; 74: 627–633
   PubMed Web of Science ®Google Scholar
• Faerber L., Drechsler S., Ladenburger S., Gschaidmeier H., Fischer W. The neuronal 5-HT3 receptor network after 20 years of research—Evolving concepts in management of pain and inflammation. Eur. J. Pharmacol. 2007; 560: 1–8
   PubMed Web of Science ®Google Scholar
• Farber L., Stratz T., Bruckle W., Spath M., Pongratz D., Lautenschlager J., Kotter I., Zoller B., Peter H.-H., Neeck G., Alten R., Muller W. Efficacy and tolerability of tropisetron in primary fibromyalgia—A highly selective and competitive 5-HT3 receptor antagonist. Scand. J. Rheumatol. 2000; 29(Suppl)49–54
   Google Scholar
• Fielding S., Wilker J., Hynes M., Szewczak M., Novick W. J., Jr., Lal H. A comparison of clonidine with morphine for antinociceptive and antiwithdrawal actions. J. Pharmacol. Exp. Ther. 1978; 207: 899–905
   PubMed Web of Science ®Google Scholar
• Galeotti N., Stefano G. B., Guarna M., Bianchi E., Ghelardini C. Signaling pathway of morphine induced acute thermal hyperalgesia in mice. Pain 2006; 123: 294–305
   PubMed Web of Science ®Google Scholar
• Guignard B., Bossard A. E., Coste C., Sessler D. I., Lebrault C., Alfonsi P., et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000; 93: 409–417
   PubMed Web of Science ®Google Scholar
• Guimaraes F. S., Chiaretti T. M., Graeff F. G., Zuardi A. W. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 1990; 100: 558–559
   PubMed Web of Science ®Google Scholar
• Hollt V. The in vivo occupation of opiate receptors. Factors Affecting the Action of Narcotics, M. L. Adler, L. Manara, R. Samanin. Raven Press, New York 1978; 207–220
   Google Scholar
• Hosoi M., Oka T., Hori T. Prostaglandin E receptor EP3 subtype is involved in thermal hyperalgesia through its actions in the preoptic hypothalamus and the diagonal band of Broca in rats. Pain 1997; 71: 303–311
   PubMed Web of Science ®Google Scholar
• Inoue M., Matsunaga S., Rashid M. H., Yoshida A., Mizuno K., Sakurada T., Takeshima H., Ueda H. Pronociceptive effects of nociceptin/orphanin FQ (13–17) at peripheral and spinal level in mice. J. Pharmacol. Exp. Ther. 2001; 299: 213–219
   PubMed Web of Science ®Google Scholar
• Inoue M., Shimohira I., Yoshida A., Zimmer A., Takeshima H., Sakurada T., Ueda H. Dose-related opposite modulation by nociceptin/orphanin FQ of substance P nociception in the nociceptors and spinal cord. J. Pharmacol. Exp. Ther. 1999; 291: 308–313
   PubMed Web of Science ®Google Scholar
• Kayser V., Guilbaud G. Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats. Brain Res. 1981; 226: 344–348
   PubMed Web of Science ®Google Scholar
• Kayser V., Guilbaud G. The analgesic effects of morphine, but not those of the enkephalinase inhibitor thiorphan, are enhanced in arthritic rats. Brain Res. 1983; 267: 131–138
   PubMed Web of Science ®Google Scholar
• Kayser V., Guilbaud G. Cross-tolerance between analgesic low doses of morphine and naloxone in arthritic rats. Brain Res. 1987; 405: 123–129
   PubMed Web of Science ®Google Scholar
• Kayser V., Besson J. M., Guilbaud G. Analgesia produced by low doses of the opiate antagonist naloxone in arthritic rats is reduced in morphine-tolerant animals. Brain Res. 1986; 371: 37–41
   PubMed Web of Science ®Google Scholar
• Kayser V., Besson J. M., Guilbaud G. Paradoxical hyperalgesic effect of exceedingly low doses of systemic morphine in an animal model of persistent pain (Freund's adjuvant-induced arthritic rats). Brain Res. 1987; 414: 155–157
   PubMed Web of Science ®Google Scholar
• Kwiatkowska M., Parker L. A., Buton P., Mechoulam R. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus(house musk shrew). Psychopharmacology 2004; 174: 254–259
   PubMed Web of Science ®Google Scholar
• Laulin J. P., Larcher A., Celerier E., Le Moal M., Simonnet G. Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur. J. Neurosci. 1998; 10: 782–785
   PubMed Web of Science ®Google Scholar
• Laulin J. P., Maurette P., Corcuff J. B., Rivat C., Chauvin M., Simonnet G. The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth. Analg. 2002; 94: 1263–1269
   PubMed Web of Science ®Google Scholar
• Lee C., Rodgers R. J. Antinociceptive effects of elevated plus-maze exposure: Influence of opiate receptor manipulations. Psychopharmacology 1990; 102: 507–513
   PubMed Web of Science ®Google Scholar
• Lewis J. W. Ring C-bridged derivatives of thebaine and oripavine. Adv. Biochem. Psychopharm. 1974; 8: 123–135
   Google Scholar
• Maeda Y., Yamada K., Hasegawa T., Kawamata Y., Uchida K., Iyo M., Fukui S., Nabeshima T. Relationship between anti-aversive effects of salmon calcitonin and plasma levels of ACTH, beta-endorphin and prostaglandin E2 in mice. Res. Comm. Chem. Pathol. Pharmacol. 1994; 83: 15–24
   PubMedGoogle Scholar
• Malfait A. M., Gallily R., Sumariwalla P. F., Malik A. S., Andreakos E., Mechoulam R., Feldman M. The non-psychoactive cannabis-constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 2000; 97: 9561–9566
   PubMed Web of Science ®Google Scholar
• Martin W. R. Opioid antagonists. Pharmacol. Rev. 1967; 19: 463–521
   PubMed Web of Science ®Google Scholar
• Nakano H., Minami T., Abe K., Arai T., Tokumura M., Ibii N., Okuda-Ashitaka E., Mori H., Ito S. Effect of intrathecal nocistatin on the formalin-induced pain in mice versus that of nociceptin/orphanin FQ1. J. Pharmacol. Exp. Ther. 2000; 292: 331–336
   PubMed Web of Science ®Google Scholar
• Nishihara I., Minami T., Uda R., Ito S., Hyodo M., Hayaishi O. Effect of NMDA receptor antagonists on prostaglandin E2-induced hyperalgesia in conscious mice. Brain Res. 1995; 677: 138–144
   PubMed Web of Science ®Google Scholar
• Nunes-de-Souza R. L., Canto-de-Souza A., Da-Costa M., Fornari R. V., Graeff F. G., Pela I. R. Anxiety-induced antinociception in mice: Effects of systemic and intra-amygdala administration of 8-OH-DPAT and midazolam. Psychopharmacology 2000; 150: 300–310
   PubMed Web of Science ®Google Scholar
• Paalzow G. H.M. L-Dopa induces opposing effects on pain in intact rats: (–)-Sulpiride, SCH 23390 or α -methyl-DL-p-tyrosine methylester hydrochloride reveals profound hyperalgesia in large antinociceptive doses. J. Pharmacol. Exp. Ther. 1992; 263: 470–479
   PubMed Web of Science ®Google Scholar
• Paalzow L. Analgesia produced by clonidine in mice and rats. J. Pharm. Pharmacol. 1974; 26: 361–363
   PubMed Web of Science ®Google Scholar
• Paalzow L. K., Paalzow G. H.M. Concentration-response relations for apomorphine effects on heart rate in conscious rats. Eur. J. Pharmacol. 1986; 88: 28–34
   Google Scholar
• Paalzow G. H.M., Paalzow L. K. Promethazine both facilitates and inhibits nociception in rats: effect of the testing procedure. Psychopharmacology 1985; 85: 31–36
   PubMed Web of Science ®Google Scholar
• Paalzow G. H.M., Paalzow L. K. Opposing effects of apomorphine on pain in rats. Evaluation of the dose-response curve. Eur. J. Pharmacol. 1983a; 88: 27–35
   PubMed Web of Science ®Google Scholar
• Paalzow G. H.M., Paalzow L. K. Yohimbine both increases and decreases nociceptive thresholds in rats: Evaluation of the dose-response relationship. Naunyn-Schmied. Arch. Pharmacol. 1983b; 322: 193–197
   PubMed Web of Science ®Google Scholar
• Paalzow G., Paalzow L. Separate noradrenergic receptors could mediate clonidine induced antinociception. J. Pharmacol. Exp. Ther. 1982; 223: 795–800
   PubMed Web of Science ®Google Scholar
• Parker L. A., Kwiatkowska M., Burton P., Mechoulam R. Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 2004; 171: 156–161
   PubMed Web of Science ®Google Scholar
• Paton W. D.M., Pertwee R. G. The pharmacology of cannabis in man. Marijana: Chemistry, Pharmacology, Metabolism and Clinical Effects. Academic Press, New York 1973; 287–333
   Google Scholar
• Pelissier T., Laurido C., Hernandez A., Constandil L., Eschalier A. Biphasic effect of apomorphine on rat nociception and effect of dopamine D2 receptor antagonists. Eur. J. Pharmacol. 2006; 546: 40–47
   PubMed Web of Science ®Google Scholar
• Protais P., Dubuc I., Costentin J. Pharmacological characteristics of dopamine receptors involved in the dual effect of dopamine agonists on yawning behaviour in rats. Eur. J. Pharmacol. 1983; 94: 271–280
   PubMed Web of Science ®Google Scholar
• Rance M. J. Animal and molecular pharmacology of mixed agonist–antagonist analgesic drugs. Br. J. Clin. Pharmacol. 1979; 7: 281S–286S
   PubMed Web of Science ®Google Scholar
• Rance M. J., Lord J. A.H., Robinson T. Biphasic dose response curve to buprenorphine in the rat tail flick assay: effect of naloxone pretreatment. Endogenous and Exogenous Opiate Agonists and Antagonists, E. L. Way. Pergamon Press, New York 1980; 387–390
   Google Scholar
• Reddy S. V.R., Maderdrut J. L., Yaksh T. L. Spinal cord pharmacology of adrenergic agonist-mediated antinociception. J. Pharmacol. Exp. Ther. 1980; 213: 525–533
   PubMed Web of Science ®Google Scholar
• Rubovitch V., Gafni M., Sarne Y. The mu opioid agonist DAMGO stimulates cAMP production in SK-N-SH cells through a PLC-PKC-Ca2 + pathway. Brain Res. Mol. Brain Res. 2003; 110: 261–266
   PubMedGoogle Scholar
• Sadee W., Rosenbaum J. S., Herz A. Buprenorphine: Differential interaction with opiate receptor subtypes in vivo. J. Pharmacol. Exp. Ther. 1982; 223: 157–162
   PubMed Web of Science ®Google Scholar
• Schreiber S., Rigai T., Katz Y., Pick C. G. The antinociceptive effect of mirtazapine in mice is mediated through serotonergic, noradrenergic and opioid mechanisms. Brain Res. Bull. 2002; 58: 601–605
   PubMed Web of Science ®Google Scholar
• Schmitt H., LeDouarec L.-D., Petillot N. Antinociceptive effects of some α -sympathomimetic agents. Neuropharmacology 1974; 13: 289–293
   PubMed Web of Science ®Google Scholar
• Siegan J. B., Sagen J. A natural peptide with NMDA inhibitory activity reduces tonic pain in the formalin model. NeuroReport 1997; 8: 1379–1381
   PubMed Web of Science ®Google Scholar
• Stromberg U. Dopa effects on motility in mice—Potentiation by MK-485 and dexchlorpheniramine. Psychopharmacologia 1970; 18: 58–67
   PubMedGoogle Scholar
• Strombom U. Catecholamine receptor agonists: Effect of motor activity and rate of tyrosine hydroxylation in mouse brain. Naunyn-Schmiedeberg Arch. Pharmacol. 1976; 292: 167–176
   PubMed Web of Science ®Google Scholar
• Suen P. C., Wu K., Xu J. L., Lin S. Y., Levine E. S., Black I. B. NMDA receptor subunits in the postsynaptic density of rat brain: Expression and phosphorylation by endogenous protein kinases. Brain Res. Mol. Brain Res. 1998; 59: 215–228
   PubMedGoogle Scholar
• Sulcova E., Mechoulam R., Fride E. Biphasic effects of anandamide. Pharmacol. Biochem. Behav. 1998; 59: 347–352
   PubMed Web of Science ®Google Scholar
• Taukulis H. K., Goggin C. E. Diazepam–stress interactions in the rat: Effects on autoanalgesia and a plus-maze model of anxiety. Behav. Neural. Biol. 1990; 53: 205–216
   PubMedGoogle Scholar
• Van Elstraete A.C., Sitbon P., Trabold F., Mazoit J. X., Benhamou D. A single dose of intrathecal morphine in rats induces long-lasting hyperalgesia: The protective effect of prior administration of ketamine. Anesth. Analg. 2005; 101: 1750–1756
   PubMed Web of Science ®Google Scholar
• Villiger J. W., Taylor K. M. Buprenorphine: Characteristics of binding sites in the rat central nervous system. Life Sci. 1981; 29: 2699–2709
   PubMed Web of Science ®Google Scholar
• Zhou Y., Sun Y.-H., Zhang Z.-W., Han J.-S. Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of μ -opioid analgesia by CCKB receptor antagonist L-365,260 in rat spinal cord. Eur. J. Pharmacol. 1993; 234: 147–154
   PubMed Web of Science ®Google Scholar